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The Blood and Marrow Transplant Clinical Trials Network
(BMT CTN) was chartered by the National Heart, Lung, and
Blood Institute and theNational Cancer Institute (NCI) in 2001
to conduct clinical trials aimed at improving the outcome of
patients undergoing hematopoietic cell transplantation
(HCT). Since its inception, activities of the BMTCTNhave been
guided by a series of State of the Science Symposia (SOSS),
conducted to determine the most important and clinically
relevant questions to be addressed by the cooperative activ-
ities of the Network. The ﬁrst State of the Science Symposium
identiﬁed 6 major questions that the BMT CTN shouldedgments on page 221.
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ty for Blood and Marrow Transplantation.consider (see Table 1). Over the following 6 years, the BMT
CTN activated 12 trials that addressed most of these ques-
tions, as well as others, and accrued more than 2000 patients
to these trials. In 2007, a secondSOSS (SOSS2) identiﬁedanew
series of 11 clinically important questions (see Table 1) [1].
Since SOSS2, the BMT CTN has developed and activated 7
studies addressing these issues, 6 of which have completed
accrual; accrual continues to the remaining study. The NCI
cancer cooperative groups developed and activated 2 addi-
tional trials endorsed by the BMT CTN addressing these
questions, 1 of which has completed accrual with 1 ongoing.
Studies addressing the ﬁnal 2 SOSS2 questions were not
initiated after further analysis determined that they were
likely not feasible at this time. Overall, the BMT CTN has
activated 33 trials addressing many of the most pressing
questions facing the HCT community, has accrued >6700
patients to trials, and has published results in 37manuscripts,
including many high-impact, practice-changing papers [2].
Table 1
Clinical Research Questions Identiﬁed at SOSS
First SOSS
1. Bone marrow versus peripheral blood for matched sibling HCT
2. Bone marrow versus peripheral blood for matched unrelated
donor HCT
3. Single versus double cord blood transplantation
4. Utility of T cell depletion of allogeneic bone marrow
5. Utility of sirolimus added to conventional GVHD prophylaxis
6. Allogeneic transplantation versus chemotherapy for older
patients with AML
SOSS2
1. Chemotherapy versus unrelated donor HCT for patients with
high-risk AML
2. Full intensity versus reduced intensity conditioning for patients
with AML
3. Chemotherapy þ dasatinib versus allogeneic HCT for patients
with Phþ ALL
4. Reduced intensity allogeneic HCT for patients with very high-risk
CLL
5. Reduced intensity allogeneic HCT for T cell lymphoma
6. Reduced intensity allogeneic HCT in children with hemophagocytic
lymphohistiocytosis
7. Autologous HCT for refractory Crohn’s disease
8. Use of viral speciﬁc T cells to treat adenoviral infections
9. Development of calcineurin-free regimens to treat chronic GVHD
10. Comparison of allogeneic HCT versus chemotherapy after
autologous HCT for patients with MM
11. Comparison of peritransplantation stress management
interventions
Phþ indicates philadelphia chromosome positive; CLL, chronic lymphocytic
leukemia.
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2014 to set a scientiﬁc agenda for the coming half decade.
Given the success of the previous 2 SOSS meetings, the 2014
SOSS followed a similar format. Brieﬂy, approximately
9 months before the meeting, a BMT CTN planning group
formed 13 committees (similar to those in SOSS2) addressing
13 major topics in HCT, and the planning group named
committee chairs and members for each committee. Com-
mittee members included cooperative group leaders, repre-
sentatives from specialized programs of research excellence,
individual cancer center leaders, and laboratory-oriented
investigators and clinical trialists. To encourage diverse
views and gain the broadest possible perspective, no indi-
vidual was permitted to serve on more than 1 committee.
Additionally, 2 external reviewers, who were not active
participants in BMT CTN activities or centers, were identiﬁed
for each committee. The planning group, committee chairs,
members, and external reviewers are listed in Table 2. Each
committee was charged with identifying up to 3 of the most
important clinical questions in their area that could be
addressed by the BMT CTN in the next few years. The com-
mittees met multiple times over the ensuing 6 months to
develop their list and to create brief documents describing
the outcomes of their deliberations. These reports were
circulated to the SOSS planning group, the other committee
chairs, and the external reviewers before the SOSS meeting.
Participation in the SOSS meeting was open to the public and
approximately 350 individuals attended. At the meeting,
each committee chair presented his or her group’s report,
following which the external reviewers presented their
views. A discussion period followed each presentation; these
discussions were open to all in attendance. At the conclusion
of the public meeting, the planning committee, committee
chairs, and external reviewers met, modiﬁed, and prioritized
the study concepts, based on the SOSS meeting discussions.
This article summarizes the individual committee reportsand a list of those trials most enthusiastically endorsed by
the symposium leadership.
COMMITTEE 1: LEUKEMIA
Current State of the Science
Leukemia is the most common indication for allogeneic
HCT and disease recurrence is the most common reason for
transplantation failure. Relapse occurs most frequently early
after transplantation before full donor immune reactivity has
occurred. Accordingly, this committee chose to focus pri-
marily on strategies to mitigate the risk of relapse in acute
myeloid leukemia (AML) after HCT based on the availability
of new agents, encouraging preliminary data, and trial
feasibility. The committee also noted that the role of allo-
geneic HCT in older patients remains unsettled.
Strategy 1: A Randomized, Double-blind, Phase III Study
of Fms-like tyrosine Kinase 3 (FLT3) Inhibition Compared
with Placebo as Maintenance Therapy in Subjects with
FLT3einternal Tandem Duplication (ITD)þ AML Who Are
in Remission after Allogeneic HCT
Hypothesis
The continued administration of FLT3 inhibition in pa-
tients with FLT3-ITDþ AML in remission after HCT is feasible
andwill prevent early relapse leading to improved leukemia-
free survival compared with placebo.
Background
Approximately 20% to 30% of patients with AML harbor an
ITD mutation in the FLT3 receptor that results in a high risk of
relapse after conventional chemotherapy [3]. Retrospective
data suggest suchpatientsmaybeneﬁt fromHCT, yet the riskof
relapse after HCT is still high [4]. Agents that inhibit FLT3
signaling are available andhavebeen tested inclinical trials [5].
Trial design
The committee proposed a phase III, randomized, double-
blind, 2-arm study to determine the clinical beneﬁt of FLT3
inhibitor monotherapy compared with placebo for patients
with FLT3-ITDþ AML who are in remission after HCT. The
primary endpoint would be leukemia-free survival with a
sample size based on a comparison of the 2 arms. A hazard
ratio of .6 was suggested.
Feasibility and logistics
This trial design would be deﬁnitive but would require a
large sample size (w500 patients) and thus necessitate a
multicenter and, possibly, multinational effort with support
from 1 of the drug manufacturers. At this time, quizartinib
appears to be the most promising agent, based on pre-
liminary efﬁcacy data [5].
Strategy 2: A Randomized, Phase III Study of Low-dose
Azacitidine Maintenance Compared with no Maintenance
in Patients with AML or Myelodysplastic Syndromes at
High Risk of Relapse after HCT
Hypothesis
Post-transplantation low-dose azacitidine maintenance
will decrease the risk of relapse after allogeneic HCT for AML
and or myelodysplastic syndromes (MDS).
Background
The hypomethylating agents 5-azacitidine (AZA) and
decitabine are clinically active against both MDS and AML
[6]. In particular, AZA prolongs survival compared with
Table 2
BMT CTN SOSS Committees and Reviewers
Committee/Position Reviewers
Committee 1: Leukemia
Chair: Steven Devine, Ohio State University Medical Center, Columbus
Members: Frederick Appelbaum, Fred Hutchinson Cancer Research Center, Seattle
Richard Champlin, MD Anderson Cancer Center, Houston
Stephen Couban, Queen Elizabeth II Health Science Center, Halifax
Marcos de Lima, Case Western Reserve University, Cleveland
John DiPersio, Washington University, St. Louis
Harry Erba, University of Alabama at Birmingham
Timothy Graubert, Massachusetts General Hospital, Boston
Guido Marcucci, Ohio State University Medical Center, Columbus
Richard Stone, Dana-Farber Cancer Institute, Boston
Martin Tallman, Memorial Sloan-Kettering Cancer Center, New York
Outside reviewers: Donald Bunjes, University of Ulm
Vanderson Rocha, Hôpital Saint-Louis, Paris
Committee 2: Lymphoma
Chair: Ginna Laport, Stanford University, Palo Alto
Members: Richard Ambinder, Johns Hopkins University, Baltimore
Timothy Fenske, Medical College of Wisconsin, Milwaukee
Richard Fisher, Fox Chase Cancer Center, Philadelphia
Brad Kahl, University of Wisconsin, Madison
John Leonard, Weill Cornell Medical College, New York
Thomas Shea, University of North Carolina, Chapel Hill
Julie Vose, University of Nebraska, Omaha
Wyndham Wilson, National Institutes of Health, Bethesda
Outside reviewers: Silvia Montoto, St. Bartholomew’s Hospital, London
Eileen Smith, City of Hope, Duarte
Committee 3: Multiple Myeloma
Chair: Sergio Giralt, Memorial Sloan-Kettering Cancer Center, New York
Members: Kenneth Anderson, Dana-Farber Cancer Institute, Boston
William Bensinger, Fred Hutchinson Cancer Research Center, Seattle
Parameswaran Hari, Medical College of Wisconsin, Milwaukee
Amrita Krishnan, City of Hope, Duarte
Carl Ola Landgren, National Institutes of Health, Bethesda
Sagar Lonial, Emory University, Atlanta
Philip McCarthy, Roswell Park Cancer Institute, Buffalo
Robert Orlowski, MD Anderson Cancer Center, Houston
Vincent Rajkumar, Mayo Clinic, Rochester
Keith Stewart, Mayo Clinic, Rochester
Outside reviewers: Nicolaus Kroeger, University Medical Center Hamburg-Eppendorf
Maria-Victoria Mateos, Salamanca University Hospital
Committee 4: Nonmalignant Disease
Chair: Harold Atkins, Ottawa Hospital Research Institute
Members: Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle
George Georges, Fred Hutchinson Cancer Research Center, Seattle
Linda Grifﬁth, National Institute of Allergy & Infectious Diseases, Bethesda
Carolyn Keever-Taylor, Medical College of Wisconsin, Milwaukee
Richard Nash, Colorado Blood Cancer Institute, Denver
Steven Pavletic, National Institutes of Health, Bethesda
Michael Racke, Ohio State University Medical Center, Columbus
Keith Sullivan, Duke University, Durham
Outside reviewers: Harry Malech, National Institute of Allergy & Infectious Diseases, Bethesda
Paolo Muraro, Imperial College/Hammersmith Hospital, London
Committee 5: Pediatric Transplantation e Indications/Approaches
Chair: Michael Pulsipher, University of Utah, Salt Lake City
Members: Stephan Grupp, Children’s Hospital of Philadelphia
Robert Krance, Baylor College of Medicine, Houston
Joanne Kurtzberg, Duke University, Durham
John Levine, University of Michigan, Ann Arbor
Parinda Mehta, Cincinnati’s Children’s Hospital
Sung-Yun Pai, Dana-Farber Cancer Institute, Boston
Kirk Schultz, University of British Columbia, Vancouver
Shalini Shenoy, Washington University, St. Louis
Michael Verneris, University of Minnesota, Minneapolis
Donna Wall, Manitoba Institute of Child Health, Winnipeg
Outside reviewers: Adriana Seber, Instituto de Oncologia Pediátrica, Sao Paolo
Paul Veys, Great Ormond Street Hospital for Children, London
Committee 6: Pediatric Transplantation e Outcomes/Late Effects
Chair: Stella Davies, Cincinnati’s Children’s Hospital Medical Center
Members: Scott Baker, Fred Hutchinson Cancer Research Center, Seattle
Farid Boulad, Memorial Sloan-Kettering Cancer Center, New York
Paul Carpenter, Fred Hutchinson Cancer Research Center, Seattle
Christine Duncan, Dana-Farber Cancer Institute, Boston
Mary Eapen, Medical College of Wisconsin, Milwaukee
(Continued on next page)
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Table 2
(continued)
Committee/Position Reviewers
David Jacobsohn, Children’s National Medical Center, Washington, DC
Amy Keating, University of Colorado, Denver
Carrie Kitko, University of Michigan, Ann Arbor
Margaret MacMillan, University of Minnesota, Minneapolis
Outside reviewers: Adriana Seber, Instituto de Oncologia Pediátrica. Sao Paolo
Paul Veys, Great Ormond Street Hospital for Children, London
Committee 7: Optimal Donor and Graft Source
Chair: Claudio Anasetti, H. Lee Mofﬁtt Cancer Center, Tampa
Members: Juliet Barker, Memorial Sloan-Kettering Cancer Center, New York
Asad Bashey, Northside Hospital, Atlanta
Claudio Brunstein, University of Minnesota, Minneapolis
Dennis Confer, National Marrow Donor Program, Minneapolis
Sarah Cooley, University of Minnesota, Minneapolis
Corey Cutler, Dana-Farber Cancer Institute, Boston
Ephraim Fuchs, Johns Hopkins University, Baltimore
John Hansen, Fred Hutchinson Cancer Research Center, Seattle
Elizabeth Shpall, MD Anderson Cancer Center, Houston
Outside reviewers: Bronwen Shaw, Anthony Nolan Research Institute, London
Gerard Socie, Hôpital Saint-Louis, Paris
Committee 8: GVHD
Chair: Joseph Antin, Dana-Farber Cancer Institute, Boston
Members: Amin Alousi, MD Anderson Cancer Center, Houston
James Ferrara, University of Michigan, Ann Arbor
Mary Flowers, Fred Hutchinson Cancer Research Center, Seattle
Richard Jones, Johns Hopkins University, Baltimore
Leslie Kean, Seattle Children’s Hospital
Paul Martin, Fred Hutchinson Cancer Research Center, Seattle
Richard Maziarz, Oregon Health & Science University, Portland
David Porter, University of Pennsylvania, Philadelphia
Daniel Weisdorf, University of Minnesota, Minneapolis
Outside reviewers: Andrea Bacigalupo, San Martino Hospital, Genoa
Ernst Holler, University Hospital Regensburg
Committee 9: Gene and Cell Therapy
Chair: Helen Heslop, Baylor College of Medicine, Houston
Members: Catherine Bollard, Children’s National Medical Center, Washington, DC
Steve Forman, City of Hope, Duarte
Edwin Horwitz, Children’s Hospital of Philadelphia
Michael Jensen, Seattle Children’s Hospital
Donald Kohn, University of California- Los Angeles
Marcela Maus, University of Pennsylvania, Philadelphia
Jeffery Miller, University of Minnesota, Minneapolis
Katy Rezvani, MD Anderson Cancer Center, Houston
Jerry Ritz, Dana-Farber Cancer Institute, Boston
Michel Sadelain, Memorial Sloan-Kettering Cancer Center, New York
Outside reviewers: Rupert Handgretinger, University of Tübingen
Armand Keating, Princess Margaret Hospital, Toronto
Committee 10: Comorbidity and RRT
Chair: Edward Stadtmauer, University of Pennsylvania, Philadelphia
Members: Andrew Artz, University of Chicago
Ami Bhatt, Dana-Farber Cancer Institute, Boston
Guang-Shing Cheng, University of Washington, Seattle
Kenneth Cooke, Johns Hopkins University, Baltimore
Vincent Ho, Dana-Farber Cancer Institute, Boston
John McCarty, Virginia Commonwealth University, Richmond
Robert Soiffer, Dana-Farber Cancer Institute, Boston
Mohamed Sorror, Fred Hutchinson Cancer Research Center, Seattle
Greg Yanik, University of Michigan, Ann Arbor
Outside reviewers: Jane Apperley, Imperial College, London
Mohamad Mohty, Hotel-Dieu, Université de Nantes
Committee 11: Infection/Immune Reconstitution
Chair: John Wingard, University of Florida, Gainesville
Members: Michael Boeckh, Fred Hutchinson Cancer Research Center, Seattle
Nelson Chao, Duke University, Durham
Mitchell Horwitz, Duke University, Durham
Kieren Marr, Johns Hopkins University, Baltimore
Richard O’Reilly, Memorial Sloan-Kettering Cancer Center, New York
Stan Riddell, Fred Hutchinson Cancer Research Center, Seattle
Marcel van den Brink, Memorial Sloan-Kettering Cancer Center, New York
Edmund Waller, Emory University, Atlanta
Outside reviewers: Per Ljungman, Karolinska University Hospital, Huddinge
John Zaia, City of Hope, Duarte
Committee 12: Late Effects/QOL/Economics
Chair: Stephanie Lee, Fred Hutchinson Cancer Research Center, Seattle
Members: Saro Armenian, City of Hope, Duarte
(Continued on next page)
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(continued)
Committee/Position Reviewers
Heather Jim, H. Lee Mofﬁtt Cancer Center, Tampa
Nandita Khera, Mayo Clinic, Rochester
Navneet Majhail, National Marrow Donor Program, Minneapolis
J. Douglas Rizzo, Medical College of Wisconsin, Milwaukee
Bipin Savani, Vanderbilt University, Nashville
Karen Syrjala, Fred Hutchinson Cancer Research Center, Seattle
Outside reviewers: Jane Apperley, Imperial College, London
Gerard Socie, Hôpital Saint-Louis, Paris
Committee 13: Clinical Trial Design
Chairs: Brent Logan, Medical College of Wisconsin, Milwaukee
Liaison to Comorbidity/RRT and Pediatric Outcomes/Late Effects Committee
Marcelo Pasquini, Medical College of Wisconsin, Milwaukee
Liaison to Gene/Cell Therapy and Multiple Myeloma Committees
Members: Tom Braun, University of Michigan, Ann Arbor
Liaison to Gene/Cell Therapy and GVHD Committees
Nancy DiFronzo, National Heart, Lung, and Blood Institute, Bethesda
Liaison to Nonmalignant Disease and Pediatric Outcomes/Late Effects Committees
Elihu Estey, Fred Hutchinson Cancer Research Center, Seattle
Liaison to Comorbidity/RRT and Leukemia Committees
Nancy Geller, National Heart, Lung, and Blood Institute, Bethesda
Liaison to GVHD and Multiple Myeloma Committees
Ted Gooley, Fred Hutchinson Cancer Research Center, Seattle
Liaison to Late Effect/QOL/Economics and Leukemia Committees
Mary Horowitz, Medical College of Wisconsin, Milwaukee
Liaison to Lymphoma and Pediatric Indications/Approaches Committees
Eric Leifer, National Heart, Lung, and Blood Institute, Bethesda
Liaison to Late Effects/QOL/Economic and Pediatric Outcomes/Late Effects Committees
Leo Luznik, Johns Hopkins University, Baltimore
Liaison to Infection/Immune Reconstitution and Optimal Donor/Graft Source Committees
Adam Mendizabal, The EMMES Corporation, Rockville
Liaison to Nonmalignant Diseases and Pediatric Indications/Approaches Committees
Joycelynne Palmer, City of Hope, Duarte
Liaison to Infection/Immune Reconstitution and Lymphoma Committees
Outside reviewers: N/A
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administer after HCT [7,8]. A phase I trial established a safe
dose after HCT and the Alliance (formerly Cancer and Leu-
kemia Group B) recently completed a 64-patient phase II
study using that dose after reduced-intensity conditioning
(RIC) HCT in patients with AML and MDS. A single-center
phase III study is ongoing at MD Anderson.
Trial design
The committee proposed a randomized phase III
study comparing subcutaneous AZA starting on post-
transplantation day 40 to 100, given in 30-day cycles for
1 year, or approximately 12 cycles, compared with no main-
tenance. Event-free survival would be the primary endpoint.
Patients who are FLT3 ITDþ would be excluded to avoid
overlap with strategy 1. A hazard ratio of .6 was suggested.
Feasibility and logistics
Sample size would depend on the magnitude of the
beneﬁt postulated, but the trial would likely require 250 to
350 patients. There are now oral hypomethylating agents
available that may increase trial feasibility and facilitate use
of a placebo control.
Strategy 3: Prospective Comparative Trial Evaluating
Postremission HCT versus Consolidation Chemotherapy
in Older Patients with AML
Hypothesis
Patients with AML in ﬁrst complete remission (CR1) who
are 60 years or older will have prolonged survival after HCT
compared with other consolidation strategies.Background
Multiple retrospective series, as well as smaller prospec-
tive studies, suggest patients 60 years or older with AML in
CR1 undergoing HCT may have superior outcomes compared
with counterparts receiving nontransplantation-based
consolidation [9,10]. These studies are confounded by dif-
ferences in selection practices for HCT and non-HCT
therapies. A deﬁnitive advantage with transplantation,
demonstrated in a large prospective trial, would change the
standard of therapy for this group of individuals.
Trial design
The committee proposed a phase III trial with 2 arms,
ancillary to any active North American cooperative group
trial for initial therapy in elderly patients (60 to 75 years
old) with newly diagnosed AML. The trial would use a
biologic assignment design. Patients with a suitable donor
would be assigned to the HCT arm. Overall survival would
be compared between those with versus those without a
suitable donor.
Feasibility and logistics
This trial design would require 500 to 600 patients at
initial diagnosis based on anticipated dropout because of
failure to respond to initial therapy and other logistical issues
that are not insigniﬁcant. The latter include the relatively low
number of older AML patients with an available donor who
actually proceed to HCT (<50%) and the recent availability of
alternative donor transplants (eg, umbilical cord blood,
haplo-identical relative), making transplantation an option
for virtually all patients.
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There was signiﬁcant enthusiasm for the concept of in-
terventions to mitigate the risk of relapse in high-risk AML
after allogeneic HCT. Both Strategies 1 and 2 were considered
meritorious and should be highpriority for the network in the
near future. Concerns were raised regarding the current
paucity of data regarding the safety and feasibility of admin-
istering FLT3 inhibitors after HCT, though phase II studies are
ongoing that should help to inform trial design. Regarding
Strategy 2, concerns were raised about the dose and schedule
as well as route of administration (oral versus parenteral) of
hypomethylating agents, but data from ongoing and recently
completed phase II studies should be available to aid in trial
design. Strategy 3 was given a lower priority because of an
inability to resolve the substantial biases inherent in a trial
design that does not allow randomization.COMMITTEE 2: LYMPHOMA
Current State of the Science
HCT cures a subset of patients with relapsed/refractory
non-Hodgkin lymphoma and diffuse large B cell lymphoma
(DLBCL) is the second-most common indication for autolo-
gous HCT (AuHCT) worldwide. Efforts to reduce relapse rates
after AuHCT for lymphoma include offering HCTearlier in the
disease course. A recently published large randomized trial
provides evidence, via a subset analysis, for the efﬁcacy of
AuHCT in CR1 for high-risk DLBCL [11]. High-risk DLBCL, such
as “double hit” (DH) lymphoma and the activated B celletype
lymphoma (ABC), is being identiﬁed earlier [12]. AuHCT is
offered in CR1 to younger patients with mantle cell lym-
phoma (MCL), but is not curative.Strategy 1: A Randomized Trial of Ibrutinib during and
after AuHCT in Patients with Relapsed and Refractory
DLBCL of the ABC Subtype
Hypothesis
Ibrutinib will improve progression-free survival (PFS) af-
ter AuHCT for patients with relapsed or refractory ABC-
subtype DLBCL.
Background
The 2 distinct subtypes of DLBCL, germinal center B
cellelike and ABC [13], have signiﬁcantly different 5-year
survival rates of 60% versus 35%, respectively, with front-
line chemotherapy with rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisone (R-CHOP). AuHCT for
relapsed and refractory DLBCL yields 2-year PFS and overall
survival rates of 48% and 65%, respectively, for patients with
chemotherapy-responsive disease [14]. Disease progression
after AuHCT remains the primary cause of failure. Ibrutinib is
a selective inhibitor of Bruton’s tyrosine kinase that achieves
responses in patients with lymphoid malignancies, including
those with heavily pretreated ABC-type DLBCL [15e17].
Trial design
The committee proposed a randomized, placebo-
controlled phase III study in patients receiving AuHCT for
ABC-type DLBCL that is chemosensitive to salvage therapy.
Patients would be randomized to receive ibrutinib or pla-
cebo. Ibrutinib would start during the pretransplantation
conditioning period and continue through 12 months after
HCT. Patients who progressed on the placebo arm would be
allowed to receive ibrutinib. The methodology to be used for
determining the cell-of-origin (gene expression proﬁling,immunohistochemistry algorithms, or nanostring technolo-
gies) would be speciﬁed before trial initiation.
Feasibility and logistics
A Center for International Blood and Marrow Transplant
Research (CIBMTR) query found that between 2009 and
2012, 770 patients per year with relapsed DLBCL underwent
AuHCT. Assuming that 50% of these patients are of ABC
subtype, approximately 335 patients per year will be eligible.
Assuming that 1 of 3 patients is eligible and will participate,
accrual of 100 patients per year is feasible. A sample size of
300 patients accrued over 3 years, with 2 years of follow-up,
would provide 85% power to detect a clinically meaningful
increase in PFS (hazard ratio of 1.6), assuming a median PFS
ofw24 months in the placebo arm [18,19].
Strategy 2: A Phase II Trial for Previously Untreated DH
DLBCL Patients: rituximab, etoposide, prednisone,
vincristine, cyclophosphamide, doxorubicin (R-EPOCH)
Induction Followed by AuHCT during First Partial
Remission (PR1) or CR1
Hypothesis
AuHCT for previously untreated patients with DH DLBCL
during ﬁrst response (CR1 or PR1) will have improved 2-year
PFS compared with DH DLBCL patients who receive con-
ventional therapy only.
Background
DLBCL patients who express concurrent MYC and BCL2
translocation or DH lymphoma have a dismal outcome. Re-
ported 3-year PFS rates range from 39% to 45%, with a 5-year
PFS of 18% [20,21]. There are no controlled trials evaluating
the impactofAuHCTearly in thedisease course. In amulticenter
retrospective study of >100 DH lymphoma patients, R-EPOCH
was superior to R-CHOP in achieving CR1. Additionally, AuHCT
in CR1 was associated with improved survival [22]. A pro-
spective study evaluating dose-adjusted R-EPOCH followed by
AuHCT in ﬁrst response would help deﬁne optimal treatment.
Trial design
The committee proposed a single-arm phase II study. The
primary endpoint would be 2-year PFS. Eligibility would
include patients with newly diagnosed DH DLBCL, identiﬁed
by ﬂuorescein in situ hybridization. Conﬁrmation of the dual
rearrangement of MYC and BCL2 would be done via a central
lab performing ﬂuorescein in situ hybridization analyses. One
cycle of chemotherapy would be allowed before starting R-
EPOCH induction. After induction and up to 6 cycles of
consolidation, patients in PR1orCR1wouldproceed toAuHCT.
Feasibility and logistics
In 2013, w21,000 cases of DLBCL were diagnosed.
Approximately 25% of these cases carried DH mutations.
Assuming a baseline 2-year PFS ofw 38%, a sample size of 46
patients would allow detection of improvement to 58% with
90% power and an a of .05. It is estimated that accrual could
be completed in less than 2 years.
Strategy 3: Therapeutic Alternatives for Mantle Cell
Lymphoma
Hypothesis
See below.
Background
Median overall survival of patients with newly diagnosed
MCL is 4 to 5 years with conventional chemotherapy [23].
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containing regimens, with younger patients often offered
AuHCT in CR1 [24,25]. Recent reports show that maintenance
rituximab after R-CHOP prolongs remission and reduces the
risk of death in older patients [26]. Additionally, mainte-
nance rituximab prolongs PFS after AuHCT, with 2-year PFS
rates approaching 90% [27]. Bendamustine/rituximab (BR) is
an increasingly used regimen conferring CR rates of w50%
with less toxicity than R-CHOP in newly diagnosed MCL [28].
The most common postremission approaches after BR in-
duction consist of maintenance rituximab and/or AuHCT.
There are no prospective studies of either approach (after BR)
and no randomized comparison of maintenance rituximab
after conventional therapy versus maintenance rituximab
after AuHCT in patients who achieve CR1. Ibrutinib is also
highly active in patients with relapsed/refractory MCL with
response rates of approximately 70% [29].
Potential trial designs
The committee discussed several possible study designs.
One concept involved performing AuHCT for MCL in CR1 and
then randomizing patients to maintenance rituximab versus
maintenance ibrutinib. The induction regimen would not be
speciﬁed. The hypothesis is thatmaintenance ibrutinibwould
signiﬁcantly extend 2-year PFS over maintenance rituximab.
Another concept involved giving previously untreated MCL
patients 6 cycles of BR induction followed by randomization
to either AuHCT after by maintenance rituximab or mainte-
nance rituximab alone. The hypothesis is that outcomes will
be equivalent between AuHCT with maintenance rituximab
versus maintenance rituximab alone. Potential pitfalls of this
concept include the requirement for patients to enroll at the
time of diagnosis, at which time they may not be at a trans-
plantation center. Also, high-dose cytarabine is not part of the
planned induction and some investigators may not feel
comfortable offering BR as induction therapy. Although the
above 2 concepts attempt to answer relevant questions,
robust point estimates are currently not available in the
literature to accurately project effect sizes.
Feasibility and logistics
A CIBMTR query showed that the numbers of MCL pa-
tients who underwent AuHCT in CR1 in 2011 and 2012 were
412 and 397, respectively. Thus, depending on the sample
size of a proposed trial, a sufﬁcient number of CR1 MCL pa-
tients may be eligible for such a trial. Both HCT physicians
and lymphoma physicians would need to reach consensus
regarding speciﬁc populations, indications, and timing of
AuHCT and the potential role of maintenance therapy after
AuHCT before a large MCL trial involving AuHCT could be
successfully launched.
Summary of Discussion
There was considerable enthusiasm for Strategy 1, eval-
uating the role of ibrutinib added to AuHCT for patients with
ABC DLBCL. Strategy 2 also was felt to be meritorious. There
was less enthusiasm for Strategy 3, for reasons described in
the sections on trial design and feasibility.
COMMITTEE 3: MULTIPLE MYELOMA
Current State of the Science
Background
The most compelling clinical question to be addressed
today inmultiplemyeloma (MM) is the role of early versus late
AuHCT. The ongoing Intergroupe Francophone du Myelome/Dana-Farber Cancer Institute randomized trial (BMT CTN
1304) is addressing this issue and is the highest priority study
identiﬁed by the BMT CTN Myeloma Intergroup Committee.
The Myeloma SOSS committee also felt that deﬁning whether
risk-adapted therapy (prognostic index þ response) can be
used to guide therapy is an important goal. Studies might
address whether “depth of response” based on multiparam-
eter ﬂow cytometry or polymerase chain reaction (PCR) pre-
dicts outcome, andwhether amyeloma riskproﬁleþ “depthof
response” can guide subsequent therapy (ie, need for high-
dose consolidation or continued maintenance) [30,31].
Finally, the committee noted that disease recurrence/pro-
gression is the single most important cause of treatment fail-
ure and continued development of post-HCT therapies that
reduce the risk of progression should be the focus of future
research. Among the strategies being considered are new
agents for post-HCT maintenance, new strategies for alloge-
neic HCT, and novel antimyeloma vaccines.
Strategy 1: A Multicenter Phase II, Placebo-Controlled
Trial of Maintenance Ixazomib after Allogeneic
Hematopoietic Cell Transplantation for High-Risk MM
(BMT CTN 1302)
Hypothesis
RIC allogeneic HCT incorporating proteosome inhibitors
in the preparative regimen and as post-transplantation
maintenance will improve PFS in patients with high-risk
multiple myeloma.
Background
Although existence of a graft-versus-myeloma effect is well
documented, the role of allogeneic HCT in MM remains to be
deﬁned. In the upfront setting, most prospective trials failed to
show a beneﬁt for allografting as consolidation of an initial
remission including theBMTCTN trial, 0102,which compared a
tandem AuHCT approach with AuHCT followed by allogeneic
HCT. Notwithstanding, long-termdisease control and cures can
be obtained with this approach, even in patients who have
failed primary therapy [32]. Moreover, long-term follow-up of
BMT CTN 0102 suggests that relapse rates may be decreased
after a RIC allograft in patients with high-risk disease. Borte-
zomib is a proteosome inhibitor that has signiﬁcant anti-
myeloma and immune modulatory activity. In phase II trials,
bortezomib can reduce the risk of grades 2 to 4 graft-versus-
host disease (GVHD) in the HLA-mismatched setting [33]. Ixa-
zomib (MLN9708) is a next-generation, small-molecule, boro-
nate proteasome inhibitor that can be given orally once aweek.
Trial design
The committee endorsed a randomized phase II trial,
already in development by BMT CTN, that will explore the
role of 2 proteosome inhibitors (bortezomib and ixazomib) in
preventing disease recurrence after allogeneic HCT in patient
with high-riskMM [34]. This trial incorporates bortezomib in
a RIC regimen to reduce the risk of GVHD and improve
myeloma control. After allogeneic HCT, patients are ran-
domized to receive either placebo or the novel oral protea-
some inhibitor ixazomib as maintenance therapy. The
primary objective is to improve 18-month PFS in patients
with high-risk myeloma (high-risk cytogenetics or ﬁrst
relapse after AuHCT) from 50% to 75%.
Feasibility and logistics
High-risk MM patients with an early relapse after auto-
grafts form a group for which all current therapies are
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will relapse within 2 years. A subset of these patients (based
on age, performance status, effectiveness of second-line
therapy) will be eligible for the proposed trial. Because
there are > 6000 AuHCTs for MM annually in the United
States, we expect there will be at least 500 post-AuHCT pa-
tients eligible each year. High-risk patients identiﬁed at
diagnosis (by genetic tests) account for 20% of all patients
with MM and another group eligible for this trial. Although
this trial will compete with several non-HCT trials, we expect
that at least 30% of newly diagnosed high-risk MM patients
will be offered this trial. Patients enrolled in alternative
nontransplantation trials would also be eligible for the 1302
trial at progression. Allogeneic HCT is not commonly per-
formed for treatment of myeloma with approximately 100
transplantations per year, according to the CIBMTR. BMT CTN
centers were surveyed to understand the challenges and
local practices. The 5 centers with the highest trans-
plantation activity for this indication were included in the
survey. The 2 most common reasons for not proceeding to
transplantation were insurance denials and lack of a clinical
trial. Twenty-nine centers conﬁrmed interest in participating
in BMT CTN 1302, with a total estimated accrual rate of 100
patients per year.
Strategy 2: Multicenter Trial Exploring the Safety and
Efﬁcacy of a Plasma CelleDendritic Cell Fusion Vaccine
Hypothesis
Dendritic celleplasma cell fusion vaccination in the post-
HCT setting will enhance antimyeloma immunity, producing
higher response rates and improved disease control.
Background
The immune system is known to play an important role
in myeloma progression and control. Recently some
myeloma vaccine trials have shown promising clinical re-
sults. Particularly encouraging is the approach described by
Avigan et al. utilizing a plasma celledendritic cell fusion
product [35].
Trial design
The committee endorsed a randomized phase II study of
post-HCT vaccination. This trial is already in active devel-
opment and is proposed to be performed in 2 stages: (1)
screening to collect plasma cells for vaccine production, and
(2) randomization to either post-HCT lenalidomide versus
post-HCT lenalidomide þ fusion vaccine administered
30 days after HCT and after the second, third, fourth, and
12th lenalidomide maintenance cycles. The primary end-
point is an increase in CR rates from 40% to 60% at 18 months
(20% effect size). To detect this effect size with a type I error
of .1, the trial will need 120 randomized patients. A 30% drop
out rate at the screening stage is expected, requiring
enrollment of 170 patients.
Feasibility and logistics
Standardized vaccine production is the main barrier to
be overcome for successful implementation of this proto-
col. Avigan et al. have shown that it is possible to export the
vaccine production technology to other sites with Good
Manufacturing Practice capabilities. Thus, this protocol will
be limited to sites with Good Manufacturing Practice fa-
cilities that have the capacity to produce the vaccine.
Likewise, vaccine production requires at least 20% plasma
cells in the marrow aspirate. This means that many patientsreferred for transplantation will not be eligible. Proactive
screening and recruitment of all newly diagnosed MM
patients will be essential for successful protocol
completion.
Strategy 3: Evaluating Risk-Adaptive Therapy for
Multiple Myeloma
The committee discussed the design of a deﬁnitive trial
addressing the role of risk-adaptive therapy for myeloma but
concluded that this should be deferred until the current early
versus late HCT trial completes accrual and the results of
BMT CTN 0702 (single AuHCT with/without revlimid, vel-
cade, dexamethasone (RVD) consolidation versus tandem
AuHCT with maintenance therapy) and the long-term
follow-up data of patients on lenalidomide maintenance in
Cancer and Leukemia Group B 100104 are available.
Summary of Discussion
The BMT CTN has a robust myeloma portfolio at this time
and is addressing the compelling question of optimal timing
of AuHCT for patients with standard-risk disease. There was
strong enthusiasm for Strategies 1 and 2, which will address
important issues such as the role of allogeneic HCT and the
use of a novel immune-therapeutic strategy to ameliorate
progression after AuHCT. The committee endorsed the
concept that follow on studies to the current BMT CTN
portfolio should explore the concepts of risk-adapted ther-
apy and further development of novel immune-therapeutic
strategies. Future protocol development should take into
consideration results from currently active clinical trials be-
ing conducted worldwide.
COMMITTEE 4: NONMALIGNANT DISEASES IN ADULTS
Current State of the Science
Nonmalignant diseases account for just 5% of HCT ac-
tivity. One half to two thirds of the procedures are per-
formed for a broad range of inherited diseases of the blood
and immune system in children. Most of the remaining are
performed for marrow failure, about one half in children.
Over the last 15 years, through numerous early-phase
observational or small randomized clinical trials, HCT
has proven a feasible and powerful tool for repairing dis-
eases characterized by dysfunctional hematopoiesis and
immunity. Despite the potential to mitigate these often
highly morbid or severe life-threatening conditions, they
remain orphan HCT indications. Well-designed, random-
ized trials could help establish the role of HCT in main-
stream clinical practice, to the beneﬁt of patients. This
committee examined adult nonmalignant disease in-
dications that would be appropriate for multicenter HCT
clinical trials.
Strategy 1: HCT for Multiple Sclerosis (MS)
Hypothesis
High-dose cytotoxic therapy with AuHCT will improve
control of relapsing-remitting MS.
Background
Patients with highly active MS achieve long-term
freedom from inﬂammatory activity and sustained accu-
mulation of disability (SAD) after AuHCT without the need
for ongoing immunotherapy. Despite evidence of effective-
ness provided by the outcome of a combined CIBMTR and
European Society for Blood and Marrow Transplantation
registry follow-up study [36,37] and numerous phase II
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by the lack of comparison to current costly immunosup-
pressive agents.
Trial design
The committee proposed a randomized phase III trial in
patients with highly active, relapsing-remitting MS and who
have moderate disability and have failed at least 1 conven-
tional disease-modifying drug to test whether ablative con-
ditioning followed by AuHCT will result in better outcomes
than the best available nontransplantation therapy. The pri-
mary endpoint would be 3-year inﬂammatory disease-free
survival (DFS) (absence of clinical relapses, absence of
gadolinium-enhancing lesions, and absence of new T2 le-
sions on magnetic resonance imaging scan). Secondary
endpoints would include freedom from SAD, sustained
improvement in disability, quality of life (QOL), and cost-
effectiveness. Sixty patients per arm are required to detect
absolute improvement in inﬂammatory DFS from 60% to 80%,
assuming 90% power with P ¼ .05. An extension study would
examine 5 to 7 year freedom from SAD and responses to
subsequent treatment for patients failing the study
treatment.
Feasibility and logistics
Although there are currently more than 300,000 patients
with MS in the United States, fewer than 50 each year un-
dergo AuHCT. Patient recruitment could be an issue, high-
lighting the importance of developing a referral network
whereby MS patients are sent to a deﬁned number of study
centers with expertise in both MS and HCT.Strategy 2: Alternative Donor HCT for Aplastic Anemia
Hypothesis
Optimizing the conditioning regimen used for umbilical
cord blood and haploidentical bone marrow trans-
plantation for aplastic anemia will result in outcomes
similar to those of unrelated adult donor bone marrow
transplantation.
Background
Survival after HLA-matched unrelated donor trans-
plantations for aplastic anemia now exceeds 80% [39,40],
leading to increased HCT referrals of patients failing immu-
nosuppressive therapy. However, up to 40% of otherwise
eligible patients, especially minorities, do not have HLA-
matched adult donors. Historically, outcomes with alterna-
tive donors have been poor [41,42]. More recently, dose- and
timing-optimized administration of antithymocyte globulin,
along with a slight increase in total body irradiation (TBI)
dose (from 2 to 4 Gy) has produced consistent engraftment of
alternative donor cells in pilot studies [43]. This affords the
possibility of offering HCT to more patients with aplastic
anemia.
Trial design
The committee proposed a phase I/II study of HCT for
aplastic anemia using haploidentical and cord blood donors,
building upon the recently completed BMT CTN 0301 trial
that optimized cyclophosphamide dosing for unrelated
donor marrow transplantations. This new trial would ﬁrst
optimize antithymocyte globulin dose and timing and then
optimize TBI dose, to minimize exposure. The primary
endpoint would be 1-year graft-failureefree survival. Thestatistical design would be ﬁnalized after analysis of BMT
CTN 0301 in late 2014, building on the latest available data.
Feasibility and logistics
Aplastic anemia is a rare disease and not all patients
require transplantation. In 2012, there were 103 matched
sibling donor, 98 unrelated donor, and 10 cord blood trans-
plantations for aplastic anemia in the United States. This trial
proposal targets the small fraction of the aplastic population
without an HLA-matched adult donor. BMT CTN 0301
required more than 30 sites to enroll 94 patients over a
period of 9 years. Thus, we anticipate that this trial would
require a national and possibly international initiative and
more than 5 years for accrual of a sufﬁcient sample size;
however, the BMT CTN is the only venue that will allow
evaluation of HCT techniques in this disease.
Strategy 3: HCT for Sickle Cell Disease
Hypothesis
Allogeneic HCT will improve long-term survival of young
adults with severe sickle cell disease (SCD).
Background
Supportive care allows most children to survive to
adulthood, but young adults with severe SCD experience
rapid disease progression and premature mortality. HLA-
matched sibling donor HCT has curative potential but is
applied sparingly. A Cochrane review identiﬁed the need for
a randomized controlled clinical trial to assess its risks and
beneﬁts [44]. Although trials of allogeneic HCT for children
with SCD exist, there is limited experience using HCT in
adults. The CIBMTR database records only 42 trans-
plantations in adults (21 years) for SCD in the period be-
tween 2008 and 2012 [45]. Limited donor availability,
regimen-related toxicity, GVHD, and high graft rejection
rates have been problematic but may be overcome by re-
ﬁnements in HCT approach [46].
Trial design
The committee proposed a phase III trial comparing HCT
with non-HCT therapy for young adults with SCD, using a
biologic assignment approach to treatment allocation, based
on availability of an HLA-matched related or unrelated
donor.
Feasibility and logistics
Technical issues, such as sibling and unrelated donor
availability, the high rate of graft rejection, concern about
GVHD, and the inﬂuence of patient comorbidities resulting
from complications of SCD all affect the feasibility of this
trial. The details of the transplantation regimen would need
to wait for the outcome of several currently ongoing feasi-
bility trials. Furthermore, trial enrollment may be affected by
caution on the part of patients and their primary care
physicians.
Summary of Discussion
Strategy 1, deﬁning the role of AuHCT for MS, garnered
signiﬁcant support and was felt to be a high priority for the
network in the near future. Concerns were raised about
recruitment and the need to engage the neurology commu-
nity. It was recognized that Strategy 2, improving the
outcome of alternative donor transplantation for aplastic
anemia, was important and only feasible through the BMT
CTN. The importance of the unmet clinical need in SCD
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trial in SCD should be prioritized as soon as the outcomes of
current feasibility trials become available.COMMITTEE 5: PEDIATRIC INDICATIONS FOR HCT
Current State of the Science
The most common indication for HCT in children is acute
lymphoblastic leukemia (ALL). Leukemia relapse remains the
most common cause of failure after HCT for childhood ALL.
Relapse is especially common in patients who have minimal
residual disease (MRD) before HCT and who do not develop
acute GVHD, a group that forms a sizable population avail-
able for clinical trials of novel interventions.
Allogeneic hematopoietic cells provide a source of
enzyme for children with inborn errors of metabolism (IEM)
and can ultimately prevent or ameliorate disease manifes-
tations. However, neurological worsening can continue
during the ﬁrst post-transplantation year before underlying
central nervous system (CNS) inﬂammation abates. Arresting
disease progression in these patients could improve long-
term neurologic outcomes.Strategy 1: Post-HCT Intervention to Prevent Relapse in
Patients with ALL
Hypothesis
Relapse after HCT for B cell ALL can be decreased by early
administration of antieB cell therapies that do not depend
upon functional adaptive immunity, followed by mainte-
nance therapy through the ﬁrst year after HCT, when relapse
risk is highest.
Background
Patients who do not develop acute GVHD by day þ55 are
at increased risk of relapse, especially if they have MRD
before HCT. According to CIBMTR data, 2-year relapse rates
are higher in children (31%) and adults (36%) without acute
GVHD compared with children (19%) and adults (26%) with
grades I to II acute GVHD. High pre-HCTMRD adds to this risk
(67% versus 35%) [47]. CIBMTR data from 2008 to 2012 [45]
and other studies [47] show that >90% of acute GVHD after
HCT with myeloablative conditioning occurs by day þ55.
Thus, a population at high risk for relapse can be identiﬁed
within 2 months of HCT. Because immune reconstitution is
incomplete early after HCT, agents that do not require the
adaptive immune system for efﬁcacy are ideal for this setting.
Moxetumomab and inotuzumab are 2 of several anti-CD22
or anti-CD19 conjugated immunotoxins with differing
mechanisms that have shown impressive single-agent ac-
tivity in refractory B cell ALL.
Trial Design
The committee proposed a 3-arm randomized phase II
protocol comparing post-HCT therapy with each of the 2
conjugated immunotoxins with a placebo control. Eligibility
would include children and adults undergoing noneT
celledepleted transplantation from any type of donor after
myeloablative conditioning for B cell ALL who are alive
without organ failure or acute GVHD at day þ55. Patients
would be stratiﬁed by pre-HCT MRD status and stem cell
source. Therapy would continue for 9 months. According to
CIBMTR data, 2-year DFS of children and adults not devel-
oping acute GVHD by day þ55 is 59% and 47%, respectively
(overall 53%). We hypothesize that the 2-year DFS would
improve from 53% to 70%. To test 2 agents against a controlwith 80% power at the 1-sided a ¼ .10 level for each com-
parison [48], 255 patients will be needed.
Feasibility and logistics
CIBMTR data show 285 patients per year undergoing HCT
withmyeloablative conditioning for non-Philadelphiaþ B ALL
alive with no acute GVHD at dayþ55. We assume 71 per year
(25%) would enroll, leading to an accrual time of 3.6 years.
Modiﬁcation of the study design to test agents sequentially
with possible expansion to a phase III trial for a given agent if
screening criteria are met could be considered, depending
upon availability of agents and feasibility of comparative
trials.
Strategy 2: Phase II Trial to Assess the Efﬁcacy of
Etanercept/Celecoxib in Preventing Post-HCT
Neurological Progression in Children with IEM
Hypothesis
Children with IEM who receive CNS-active anti-inﬂam-
matory agents before and after HCT will experience reduced
demyelination and better neurological outcomes.
Background
Myelination is essential for normal brain function and is a
cornerstone of human neurodevelopment [49]. Disease sta-
bilization after HCT in IEM patients is dependent upon
engraftment of donor-derived microglia, which occurs
slowly over the ﬁrst post-HCT year. Disease progression/
demyelination occurring the ﬁrst year after transplantation is
common and thought to be related to persistent CNS
inﬂammation caused by accumulation of toxic metabolites
from the underlying disease process. Preclinical studies show
that this inﬂammation is mediated by TNF-a and through the
COX-2 pathway [50]. Coadministration of agents blocking
these pathways improves myelination in animal models of
these diseases.
Trial design
The committee proposed a phase III trial in patients with
IEM randomizing patients to receive etanercept þ celecoxib
before and after allogeneic HCT versus not. The primary
endpoint would be change in myelination from pre-HCT
baseline to 6 months measured after HCT by magnetic
resonance imagingebased quantitative susceptibility map-
ping [51]. Twenty-nine patients in each arm would provide
80% power with a 2-sided a ¼ .05 to detect a .75 standard
deviation difference.
Feasibility and logistics
CIBMTR data show that 47patients with these diagnoses
undergo HCT annually. Assuming a participation rate of 40%,
accrual could be completed in 3 years. One potential problem
is the reluctance to randomize to the control arm, as the
experimental agents are readily available outside the
research setting.
Summary of Discussion
There was strong support for the post-HCT relapse pre-
vention strategy in ALL because of compelling preliminary
data and simplicity of design, although safety data for spe-
ciﬁc agents given as early as 2 months after HCT are lacking.
The discussion group also encouraged the inclusion of adults
in this study. There was less enthusiasm about the IEM
proposal because of the possibility that inﬂammationmay be
needed after HCT to facilitate engraftment and, possibly, for
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felt that more preliminary data are required to justify this
approach.
COMMITTEE 6: PEDIATRIC OUTCOMES
Current State of the Science
Most pediatric HCT recipients are surviving long-term but
long-term toxicities are a problem, especially those linked to
glucocorticoid therapy for GVHD, particularly chronic GVHD.
Speciﬁc strategies are necessary to deal with GVHD in chil-
dren, as opposed to allowing accrual of modest numbers of
older children onto GVHD trials primarily focused on adults.
Children may have different dosing requirements and
response to therapies and brisker immune reconstitution
than adults [52]. Infants and small children have increased
body surface area to weight ratios relative to adults and,
consequently, receive higher drug doses when dosed by body
surface area, with potentially increased toxicity [53,54]. Key
drug metabolizing enzymes develop throughout childhood,
being less active at some ages than in adults, yet more active
at other ages [55]. Toxicities, such as impaired growth and
disruptive behavior have increased importance in children
compared with adults. These important nuances are likely to
be lost when children constitute a subpopulation of a large
adult study, and they likely deter enrollment of children onto
adult studies. Focusing on the most promising avenues likely
to improve pediatric outcomes and endpoints is necessary.
Strategy 1: Daily versus Alternate Day Dosing of Steroids
in Chronic GVHD
Hypothesis
Every-other day prednisone regimens lower the total
cumulative dose of prednisone at 6 months and reduce
toxicity.
Background
Despite being debated for 2 decades, the question of
whether daily or alternate day steroid dosing is best for
chronic GVHD remains unanswered. The committee con-
ducted a survey that showed that 54% of respondents use
alternate day and 46% use daily steroids, conﬁrming lack of
agreement. The case for alternate day dosing derives from
old, poorly controlled literature comprising, primarily, case
series in non-HCT populations. An answer to this question
could not only unify practice but also inform the design of
future clinical trials intent on testing novel steroid-sparing
agents.
Trial design
The committee proposed a randomized phase II trial
comparing daily to alternate day steroids for chronic GVHD,
with speciﬁed criteria for proceeding to phase III. Both arms
would follow speciﬁed taper schedules, unless over-ridden
by patient tolerance. The primary endpoint will be a com-
parison of body mass index Z-scores between children in
each arm at 6months. Demonstration of a .5 reductionwould
require about 150 patients (75 per arm). Secondary end-
points would evaluate steroid toxicities via calendar-driven
measurements of bone health (development of avascular
necrosis, or dual-energy x-ray absorptiometry (DEXA) scan
Z-scores <2.0), anthropometry (height velocity, total body
fat by DEXA scan, arm-muscle area changes over time),
number and type of behavioral interventions, myopathy (5-
point manual muscle test and other simple physical ther-
apy tests), number of medicines to control hypertension,hyperglycemia, and infection rates (invasive fungal, viral,
bacterial).
Feasibility and logistics
Sample size estimates are based on the desire to
demonstrate a .5 reduction in body mass index Z-score.
There are approximately 300 children with chronic GVHD
diagnosed annually. Enrollment of 20% would allow accrual
of the necessary sample size in fewer than 2.5 years. A survey
of tapers prescribed by 3 representative pediatric institutions
suggests similar total prednisone exposures regardless of
schedule, suggesting that a trial addressing schedule,
without confounding by dose, is feasible.
Strategy 2: Bortezomib for the Prevention of Acute GVHD
Hypothesis
Three doses of bortezomib given on days 1, 4, and 7 after
transplantation will reduce the incidence of acute GVHD by
50% in children receiving transplantationwith myeloablative
conditioning.
Background
A study in adults suggests that the incidence of acute
GVHD can be reduced and immune reconstitution improved
with use of bortezomib in the early post-HCT period [33].
Trial design
The committee proposed a randomized phase II trial
enrolling children up to age 18 years old undergoing allo-
geneic umbilical cord, blood, or marrow transplantation after
a myeloablative preparative regimen. Patients would receive
either a standard calcineurin inhibitor (CNI) plus metho-
trexate or mycophenolate mofetil regimen or a similar
regimen with the addition of bortezomib on days þ1, þ4,
and þ7. The primary endpoint would be incidence of acute
GVHD at day 100. Given an expected grade 2 to 4 acute GVHD
rate of 50%, the goal is to reduce grades 2 to 4 GVHD to 25%,
which would require 74 patients per arm. Secondary end-
points would include extensive chronic GVHD and time to
recovery of normal lymphocyte counts.
Feasibility and logistics
CIBMTR data indicate that there are 300 eligible children
annually. If 75 enroll per year, accrual could be completed in
2 years.
Summary of Discussion
The importance of developing methods to reduce late
toxicities associated with prolonged steroid use in children is
clearly recognized. The facts that steroids are widely used
and that there are no studies deﬁning the best approach
make Strategy 1 of great interest and this proposal was met
with high enthusiasm. There was less enthusiasm for Strat-
egy 2, based, in part, on the view that the wide variability in
stem cell sources (cord, related, unrelated), preparative reg-
imens and disease types required to allow the study to be
conducted in a timely fashion could obscure any possible
beneﬁt of the experimental intervention.
COMMITTEE 7: OPTIMAL DONOR AND GRAFT SOURCE
Current State of the Science
The lack of histocompatible graft sources is a major lim-
itation to the treatment of hematological or immune disor-
ders with allogeneic HCT.
Table 3
Cord Blood Priming on Expansion Trials
Strategy Trial Phase, Number of Cord Blood Units Expected
Completion
Ex vivo expansion with mesenchymal cells plus cytokines [59] Phase III, multicenter, randomized, double unit >24 mo
Ex vivo priming with dimethyl-PGE2 [60] Phase II, multicenter, randomized, double unit >24 mo
Ex vivo expansion with notch ligand, freshly cultured or off-the-shelf
products [61]
Phase II, multicenter, randomized, double unit >24 mo
Recipient treatment with dipeptidylpeptidase (DPP)-4 inhibitor [62] Phase II, multicenter, single >24 mo
Ex vivo priming by fucosylation [63] Phase II, multicenter, double unit 6-12 mo
Ex vivo expansion with nicotinamide inhibitor, retains T cells [64] Phase II, single-center, single unit 6-12 mo
Cotransplantation of CD34þ cells from HLA haplo-mismatched donor,
myeloablative regimen [65]
Phase II, single-center, double unit 6-12 mo
Cotransplant of CD34þ cells from HLA haplo-mismatched donor, RIC [66] Phase II, single-center, single unit 6-12 mo
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transplantation Cyclophosphamide
Hypothesis
Post-transplantation cyclophosphamide (PTCY) prevents
GVHD lethality of HLA-disparate, noneT celledepleted
related donor HCT in myeloablated hosts, and it produces
outcomes similar to those of HLA-matched volunteer donor
transplantations.
Background
PTCY controls alloreactivity safely and effectively across
HLA disparity [56,57]. Although mostly utilized after non-
myeloablative conditioning, the 1-year survival is 60% in
younger patients after ablative conditioning [58]. An adult
relative who shares 1 HLA haplotype is almost universally
available for patients without an HLA-matched donor;
availability of the latter type of donor is limited, particularly
for patients from minority populations.
Trial design
The committee proposed a single-arm phase II study of
HCT with conditioning including myeloablative doses of TBI
or busulfan, haploidentical marrow or blood stem cell grafts,
and PTCY followed by tacrolimus/mycophenolate mofetil
maintenance. The population would include patients
60 years of age with adequate organ function, low comor-
bidity, and hematologic malignancies in CR or with minimal
disease. Primary endpoint is 1-year survival. With a sample
size of 62, the 2-sided 90% conﬁdence interval of 1-year sur-
vival is 50% to 70%, and the power is 84% to rule out a survival
of <43% with a 2-sided a ¼ .10. An exploratory analysis will
compare survival of trial patients with HLA-matched unre-
lated donor HCT recipients from the CIBMTR database.
Feasibility and logistics
Based on experience with BMT CTN 0603, which evalu-
ated use of PTCY and haploidentical donors with RIC and
accrued rapidly, and the wider use of myeloablative than RIC
regimens, the study is expected to complete accrual within
18 months.Strategy 2: Facilitate Engraftment of HLA-Disparate Cord
Blood Transplantation
Hypotheses
Recipient conditioning, or ex vivo cord blood priming or
expansion, or cotransplantation of third-party progenitors
facilitate cord blood cell engraftment.
Background
Cord blood engraftment is delayed and graft failure is
more frequent than it is after adult donor allografts,contributing to increased patient morbidity and mortality.
Eight ongoing trials address this unmet need (see Table 3).
The ﬁrst 3 in the table are in more advanced stages of
development.
Recommendation
Because of the relatively scarce population of adult pa-
tients receiving cord blood transplantation, the committee
recommended that BMT CTN and other cord blood in-
vestigators collaborate to enroll eligible patients onto 1 or
more of these potentially practice-changing open trials to
facilitate timely completion. Suggested criteria for the most
promising strategies are: (1) favorable single-center data, (2)
likely to improve transplantation effectiveness and resource
utilization, (3) exportable, (4) applicable to children and
adults, and (5) effective independently of conditioning or
immunosuppression regimens.Strategy 3: Optimize HLA-DPB1 Compatibility for Nearly
Every Patient with an Unrelated Donor
Hypothesis
The probability of identifying a permissive DPB1
mismatch (or DPB1match) increases from 70%without DPB1
typing to 90% by testing up to 10 donors per patient.
Background
More than 80% of unrelated donors matched for HLA-A/B/
C/DRB1 are mismatched for DPB1 alleles sharing a T cell
epitope (TCE) that are poorly stimulatory (permissive),
whereas others are stimulatory (nonpermissive) [67]. Mis-
matching for nonpermissive DPB1 alleles is associated with a
w15% increase in mortality risk after transplantation [68,69].
Identifying a donor that is matched or has a permissive
mismatch at DPB1 could improve survival byw5%.
Trial design
The committee recommended a prospective single-arm
trial in which DP testing would be done on multiple donors
(for patients with multiple A, B, C, and DRB1-matched do-
nors) to determine how many patients ﬁnd a donor with a
permissive-DPB1mismatch and howmany donors should be
typed based on the patient DPB1 TCE. A sample of 460 pa-
tients would provide 99% power to test the primary hy-
pothesis that the probability of a permissive mismatch
increases from 70% to 90% with alpha of .05 and allow
adequate subset analyses by TCE groups. For example, there
will be 95% power with alpha of .02 to detect an increase in
the probability of a permissive mismatch from 7.8% to 30% in
the rarest TCE-subset. The protocol will also consider donor
age, gender, and cytomegalovirus (CMV) serology and their
inﬂuence on donor selection. Patient and donor DNA also
Figure 1. The overall trial design depends on assignment to a high- or low-risk
group based on GVHD grade and biomarkers. High-risk patients will be treated
with prednisone, and new agents will be serially studied by addition to
standard prednisone therapy. Low-risk patients will be randomized between a
prednisone monotherapy or 1 of several single-agent nonsteroid alternatives.
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the killer immunoglobulin-like receptors [70,71].
Feasibility and logistics
A retrospective study addressing similar questions would
require substantially fewer resources.
Summary of Discussion
Based on available preliminary data, there was consider-
able enthusiasm for Strategy 1. Likewise, the committee
generally agreed with the approach described in Strategy 2;
there is a great need to improve the outcome of cord blood
transplantation and several of the trials underway show
promise. Given that these studies are already established and
accruing, it is reasonable for the BMT CTN to encourage its
members to participate in the most promising studies.
Although Strategy 3 had merit, it was felt that similar infor-
mation might be gained with fewer resources by doing a
retrospective study.
COMMITTEE 8: GVHD
Current State of the Science
GVHD prophylaxis
An optimal GVHD prophylaxis regimen would effectively
prevent both acute and chronic GVHD while allowing an
effective graft-versus-tumor response and prompt immu-
nologic reconstitution. BMT CTN 1203 and 1301 are designed
to test new strategies previously developed in single in-
stitutions; accrual to these trials, projected to complete in
2015 and 2017, respectively, should have highest priority.
Other strategies developed during the next 5 years could be
similarly adopted for testing in BMT CTN trials.
Acute GVHD therapy
BMT CTN 0302 and 0802 (the latter closed for futility)
failed to identify a strategy superior to single-agent predni-
sone to ameliorate the inﬂammatory effects of acute GVHD
while avoiding the mortality of severe immunosuppression.
This remains an important goal.
Chronic GVHD therapy
BMT CTN 0801 is a phase II/III study based on the hy-
pothesis that avoidance of CNIs in the treatment of chronic
GVHDmight facilitate tolerance and improve GVHD response
rates compared with conventional CNI-containing immu-
nosuppressive therapy. After interim analysis of data from
the phase II portion of this trial, it was decided to discontinue
accrual, although patients are being followed for the estab-
lished phase III endpoints. While awaiting these data, addi-
tional agents may be tested in phase II studies.
Strategy 1: Validation of a Biomarker/Clinical Scoring
System to Identify Patients at High and Low Risk of
Response to Current Acute GVHD Therapy
Hypothesis
Patients can be segregated at diagnosis of acute GVHD
into 2 or more groups with different likelihoods of response
to therapy using currently available clinical and laboratory
assessments.
Background
Therapy trials are limited by the inability to determine
prognosis accurately at onset of acute GVHD. The original
grading system correlated nonrelapse mortality (NRM) with
maximal GVHD grade, which is affected by the response totreatment. Dichotomization into standard risk or high risk at
the onset of GVHD is done implicitly inmany centers andwas
formalized recently by the Minnesota group [72]. The Min-
nesota system identiﬁes 15% of patients as high risk (with
41% versus 18% 6-month NRM) with similar ﬁndings in
several independent cohorts from BMT CTN 0302, 0802, and
2 large centers (n ¼ 1718). A newly described Ann Arbor
grading system [73] uses clinical features and biomarkers in
an algorithm that assigns patients into 3 risk groups con-
taining 35% (low risk), 40% (intermediate risk), and 25% (high
risk) of patients. The algorithm discriminated the 3 risk
groups in 2 separate validation cohorts. The highest risk
category was associated with 45% NRM at 6 months. The
algorithm was validated in 2 datasets, 1 from 2 centers, and
another including 300 patients from BMT CTN 0302 and
0802 who had plasma samples available.
Trial design
The committee proposed that a study be conducted in
conjunction with BMT CTN 1202 (Prospective Multi-Center
Cohort for the Evaluation of Biomarkers Predicting Risk of
Complications and Mortality Following Allogeneic HCT) to
validate a biomarker-based approach to risk stratiﬁcation in
protocols 1203 and 1301. Validation of the Ann Arbor grading
system or any other prognostic factors would have important
implications for future clinical trials testing new approaches
for treatment of acute GVHD. Accurate identiﬁcation of high-
risk patients at the onset of GVHD would make it feasible to
accrue patients to trials testing experimental agents in
smaller phase II trials with a robust endpoint of 6-month
NRM. Simultaneously, accurate identiﬁcation of low-risk
patients would make it feasible to test whether lower or no
glucocorticoid doses (or other approaches) could control
GVHD while minimizing steroid-related complications. The
general strategy is outlined in Figure 1.Strategy 1A: Develop an Approach to Identify Patients at
High Risk of Life-threatening Acute GVHD and Enroll
Them in Serial Studies of Agents that Work in Synergy
with Prednisone
Hypothesis
Addition of agents to prednisone will increase the effec-
tiveness of therapy for newly diagnosed high-risk acute
GVHD.
Trial design
Agents such as natalizumab, tofacitinib, abatacept,
mesenchymal stem cells, extracorporeal photopheresis, and/
or others can be tested sequentially in the high-risk cohort.
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control, assuming a day 28 CR rate of 15%, using 1-sided
signiﬁcance level of 15%, with 85% power to detect an in-
crease in day 28 complete remission rate to 35%, we would
need 49 patients per group.
Strategy 1B. Develop an Approach to Identify Patients at
Low Risk of Life-threatening Acute GVHD and Enroll
Them in a Study Designed to Limit Immunosuppression-
related Toxicity [74]
Hypothesis
Patients with low-risk GVHD can be effectively treated
with lower doses of immune suppression that minimize
toxicity.
Trial design
The committee proposed a study to randomize primary
therapy of acute GVHD to prednisone or sirolimus [75]
basiliximab or another agent to determine whether a
nonsteroid-containing regimen would provide equivalent
control of GVHD with less corticosteroid-related toxicity. A
randomized phase II trial of a new agent compared with
control in low- or intermediate-risk patients, assuming a day
28 CR rate in the range of 40% to 65%, using 1-sided signiﬁ-
cance level of 15%, with 85% power to detect an increase in
day 28 CR rate to 75%, would require 58 patients per group.
Feasibility and logistics
High-risk GVHD occurs in 15% to 25% of patients and low-
risk GVHD occurs in 35% to 40% of patients; therefore, there is
likely to be an adequate population to study. The design re-
quires tight correlation with BMT CTN 1202 and real-time
biomarker information. Critical to the success of this design
is sufﬁcient ﬂexibility to allow serial studies that will facili-
tate rapid assessment of several drugs. Criteria to choose
study drugs will include completion of phase I or II testing, a
rational basis for targeting GVHD, known activity in an
immunologic or inﬂammatory disorder, and drug availability.
Strategy 2: Evaluation of Novel Agents for Chronic GVHD
Background
There are candidate drugs studied outside of the BMT CTN
that may be useful in the therapy of chronic GVHD.
Interleukin-2 has phase I/II data that support a trial in early
onset chronic GVHD [76]. Proteasome inhibitors have activ-
ity, but the drug, schedule, and timing need to be assessed
[77]. Ibrutinib has activity that is theoretically interesting
and a pilot study has been organized. Additional drugs can be
evaluated once there are adequate preliminary data.
Summary of Discussion
Although there are considerable logistic concerns, the
overall proposed strategies generated a high level of enthu-
siasm. Ways to diminish some of the barriers are discussed
by Committee 13 (Clinical Trial Design).
COMMITTEE 9: CELL AND GENE THERAPY
State of the Science
Cell therapy has made rapid recent progress with
immunotherapy being designated as the “advance of the
year” by Science in 2014 [78]. In 2010, BMT CTN sponsored a
meeting on CD19 chimeric antigen receptor (CAR) strategies
[79]. Initial reports showing activity in lymphoma and
chronic lymphocytic leukemia were published in 2010 and
2011 [80,81]. In the last year, several papers [82,83] showedeven more encouraging response rates in ALL, resulting in
the ﬁrst 2 cell therapy proposals approved by BMT CTN for
further development. These studies will evaluate T cells
genetically modiﬁed to express CARs speciﬁc for CD19 in
relapsed ALL after transplantation [83] or in patients with
active disease to induce remission and enable trans-
plantation. Multicenter cell and gene therapy studies have
particular challenges as they require Investigational New
Drug applications as well as production and shipping of cells,
clinical grade vectors, and identiﬁcation of sources for crucial
ancillary reagents.
The committee reviewed a broad cadre of cell and gene
therapy approaches for translation to future BMT CTN studies.
There are several phase I studies evaluating regulatory T cells
[84,85], but it was felt that more datawere needed to identify
the optimum cell type and clinical setting for a multicenter
trial. Gene transfer to hematopoietic stem cells to treat im-
munodeﬁciency diseases is being evaluated through small ad
hoc international consortia, which are the appropriate venues
for such diseases. Gene therapy for b-thalassemia or SCD,
however, clearly falls within the purview of BMT CTN and
several phase I trials testing different strategies and vectors
will soon open. Although data from these studies are needed
to determine the optimal approach for later phase testing,
such results may be available within the next 2 to 3 years and
BMT CTN should be prepared to deﬁnitively test these stra-
tegies. Similarly, results of the 2 currently planned CD19 CAR
studies will be needed to guide the design of the next study of
genetically modiﬁed T cells targeting CD19.
Strategy 1: Trial of Third-Party CMV-speciﬁc T Cells (Joint
Proposal with Infection Committee) [86,87]
See Infection Committee.
Strategy 2: Bridging Trial of Haploidentical Donor
Natural Killer Cells for AML Patients with Active Disease
before Transplantation
Hypothesis
Lymphodepleting chemotherapy and infusion of related
donor haploidentical natural killer (NK) cells will induce
clinical remission in patients with refractory AML.
Background and signiﬁcance
The University of Minnesota has treated more than 50
AML patients who failed standard therapy with the objective
of achieving a CR as a bridge to transplantation. Data suggest
that short-term success, deﬁned as remission induction, is in
the 25% to 50% range in small studies exploring different
platforms [88]. One difﬁculty in interpreting these studies is
the inability to separate antileukemia activity of the
chemotherapy regimen from the NK cells. A study comparing
chemotherapy  NK cells is needed to deﬁnitively address
the role of NK cells as a bridging therapy in AML with re-
sidual disease before transplantation. Additionally, we need
to understand the optimal NK cell product [89,90].
Trial design
The committee proposed a randomized phase II study in
patients with persistent refractory AML (up to 30% blasts on
bone marrow within preceding 21 days) having received >2
cycles of standard induction chemotherapy. Arm 1 patients
would receive lymphodepleting chemotherapy alone
(cyclophosphamide 50 mg/kg  2 and ﬂudarabine 25 mg/
m2  3). Arm 2 would receive the same chemotherapy but
with haploidentical freshly isolated and activated NK cells.
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expanded NK cells. All arms would receive IL-2 (or IL-15) to
promote in vivo expansion of endogenous or infused NK
cells. The primary endpoint would be achievement of CR and
an important secondary point would be the ability to pro-
ceed to allogeneic transplantation.
Feasibility and logistics
Assuming a baseline CR in this population of 20%, 38
patients per arm (total of 114) will result in 80% power with a
1-sided type I error of 5% to detect an improvement of 20%
(20% to 40%) in the CR rate. There is a possibility of obtaining
IL-15 for this trial, a cytokine believed to be superior for NK
cell in vivo expansion.
Strategy 3: Phase III Randomized Trial of Autologous
Epstein-Barr Virusespeciﬁc T Lymphocytes after AuHCT
for Patients with EpsteineBarr encoding regionein situ
hybridization (EBER-ISH)ePositive Hodgkin Lymphoma
Hypothesis
Infusion of autologous cytotoxic T lymphocytes enriched
against Epstein-Barr virus (EBV) type II latency antigens after
AuHCT for patients with EBER-ISHepositive Hodgkin lym-
phoma (HL) will result in an improved event-free survival
compared with control patients.
Background and signiﬁcance
AuHCT achieves a 2-year PFS rate of approximately 60% in
patients with relapsed HL. Approximately 30% to 40% of pa-
tients with HL are EBER-ISH positive. Adoptive transfer of
latent membrane protein (LMP)-speciﬁc T cells results in
increased frequency of relevant EBV-antigenespeciﬁc T cells
and memory T cell populations provide sustained antitumor
responses [91].
Trial design
The committee proposed a multicooperative group ran-
domized phase III study in patients with EBER-ISH positive
HL. With 164 patients (82 per arm), considering a baseline 2-
year PFS of 60% to 70%, the study has 80% or higher power to
detect a 20% improvement in 2-year event-free survival at
.05 signiﬁcance level based on a 2-sided Z-test with binomial
distribution.
Feasibility and logistics
According to CIBMTR, >800 patients per year in the
United States undergo AuHCT for HL. If 25% are EBER-ISH
positive, there would be 200 eligible patients per year
making planned accrual of 80 to 100 feasible.
Summary of Discussion
The review of Strategy 1 is covered by Committee 11.
Strategy 2 was viewed with enthusiasm because a multi-
center study is the only way to compare 2 NK products that
have been developed through an NCI-funded program proj-
ect grant and the National Heart, Lung, and Blood Institute
Production Assistance for Cellular Therapy program, but
there will need to be process development to ﬁnalize the
manufacturing and accessory cytokines before the study can
be initiated. Although there was support for Strategy 3,
which was developed through an NCI lymphoma specialized
programs of research excellence, the sample size could not
be calculated without knowing if the outcome after AuHCT
differs for EBV-positive and EBV-negative HL patients [92].
This analysis is planned. Additionally, the analysis may beconfounded if HL patients are receiving other maintenance
therapies, such as brentuximab.
COMMITTEE 10: COMORBIDITY AND REGIMEN-RELATED
TOXICITY
Current State of the Science
Efforts to decrease regimen-related toxicity (RRT) have
focused on reducing regimen intensity rather than direct
prevention or early treatments. Nevertheless, mortality from
pulmonary, hepatic, gastrointestinal, and other RRT remains
too frequent [93]. Although a signiﬁcant fraction of younger
patients with hematologic cancers are offered HCT, only a
small minority of those 60 years or older receive HCT, despite
the higher frequency of most hematologic cancers in this age
group. Objective and reliable recipient health status mea-
sures are necessary to guide decision-making about trans-
plantation eligibility and selection of the most appropriate
transplantation strategy in older patients. Additionally, early
detection and evaluation of organ dysfunction after HCT
holds promise to improve outcome.
Strategy 1: Improving Prognostic Assessment for Patients
60 Years and Older Undergoing Allogeneic HCT
Hypothesis
Adding functional assessment and biomarkers to vali-
dated clinical indices will improve the ability to predict NRM
and RRT in older patients.
Background and signiﬁcance
Validated comorbidity indices (such as the HCT-speciﬁc
comorbidity index, HCT-CI) substantially improved predic-
tion of transplantation-related organ toxicities and NRM in
adults undergoing allogeneic HCT [93e97]. Emerging data
suggest the value of other measures to risk stratify patients
including geriatric assessment (GA), which adds a functional
and ability assessment, plasma biomarkers (particularly c-
reactive protein, ferritin, and albumin), and genetic or
epigenetic modiﬁcations [98e100]. We hypothesize that a
composite health status risk score comprising GA, HCT-CI,
and biomarkers could better predict NRM and RRT leading
to improved interpretation of clinical studies, identiﬁcation
of populations for future investigations, better allocation of
patients to different transplantation strategies, and
improved HCT outcomes.
Trial design
The committee proposed a study designed to improve
risk assessment for NRM. Patients 60 years undergoing
allogeneic HCT will be evaluated before HCT with validated
GAmeasures that capture physical, mental, social, emotional,
and functional health; HCT-CI scores; plasma biomarkers (c-
reactive protein, ferritin, and albumin); and also have cells
banked for future whole genome and epigenetic screening.
Functional and QOL evaluation will be performed every
6 months for 2 years. The study is designed for the following
reasons: (1) to develop a composite model with a c-statistic
estimate >.85 to predict NRM, and (2) to test the model’s
prediction of secondary outcomes including overall and
functional free survivals, QOL, and RRT. A sample of 700
patients will be used to develop the model to ensure
adequate statistical power. Established thresholds for GA
tools and cut-off values for the biomarkers will be used for
modeling. Bootstrapping method will be used to estimate
bias-corrected values of c-statistic for internal validation of
the model.
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This study is envisaged to be open to enrollment to most
patients, whether or not they are enrolled on another BMT
CTN trial. Some of the biomarker data are already collected
routinely or in BMT CTN 1202. GA can be completed by pa-
tients on paper, electronically, or over the telephone, and
functional tests take 5 minutes by a research assistant. Suc-
cessful creation of the validated HCT-CI used similar methods
and similar sample size.
Strategy 2: Novel Approaches for Diagnosis,
Classiﬁcation, and Biologic Assessment of Late-Onset
Pulmonary Toxicity after HCT
Hypothesis
Early detection of pulmonary dysfunction after allogeneic
HCT will improve outcomes.
Background and signiﬁcance
Lung injury contributes signiﬁcantly to morbidity and is
the most common RRT cause of mortality after allogeneic
HCT. Late-onset pulmonary complications (LOPC) are
particularly problematic, including bronchiolitis obliterans
syndrome and restrictive lung disease. Inconsistencies in
terminology and diagnostic criteria contribute to a wide
variation in early detection of these complications and a false
impression of low incidence. Optimal monitoring and treat-
ment for LOPC are not established and only 1 NIH symptom-
based lung score (dyspnea) correlates with outcomes [101].
Once symptoms of LOPC occur, prognosis is poor [102e105].
New therapeutic strategies for bronchiolitis obliterans syn-
drome and restrictive lung disease hold promise for
improved outcome, but early intervention is required to
affect survival [106e109]. New imaging techniques andmore
frequent monitoring of pulmonary function utilizing readily
available devices can detect lung changes earlier.
Trial design
The committee proposed an observational study deter-
mine whether an aggressive post-HCT monitoring program
with a novel imaging biomarker will detect subclinical lung
dysfunction early (3 to 6 months after HCT) and more
frequently (20% to 30%) relative to historical controls. The
incidence of late onset, noninfectious lung disease utilizing
conventional methods is 10% to 15%, and earliest detection is
usually after the development of symptoms (1 to 2 years after
HCT), when prognosis is poor. Patients undergoing allogeneic
HCTwill undergo pulmonary function tests (PFTs) andplasma
sampling before transplantation, at day 100, and every
3 months for 2 years. Hand-held spirometry will be used
between conventional PFTs, with speciﬁc criteria for early
PFTs [101,110]. A persistent 15% decline in forced vital capac-
ity, forced expiratory volume in 1 second, or carbonmonoxide
diffusing capacity will initiate work-up including high-
resolution computed tomography (HRCT), broncho-alveolar
lavage, collection of broncho-alveolar lavage ﬂuid, blood
and stool samples for biomarker analysis, and next-
generation sequencing for pathogen discovery. Digital HRCT
ﬁles will be analyzed by a sensitive attenuation mapping
technique [111]. Patientswith noninfectious lung dysfunction
will be available for state-of-the-art intervention.
Feasibility and logistics
A sample size of 300 subjects is expected to have sufﬁ-
cient power to determine whether early detection is
possible. Broad eligibility criteria will ensure rapid accrual.The universal availability of PFTs and HRCT scans and the
ease of biomarker collection suggest this study is feasible.
Strategy 3: Identifying Microbiological “Biomarkers” that
Predict RRT
Hypothesis
Oligoclonality of the microbiome predicts poorer out-
comes after HCT. Additionally, microbes that predict adverse
outcomes or promote RRT can be identiﬁed allowing early
intervention.
Background and signiﬁcance
Our understanding of the underlying pathobiology of
gastrointestinal and pulmonary complications after HCT re-
mains incomplete [112,113]. Despite the susceptibility of the
post-HCT population to infections, efforts to characterize
microbial triggers are limited. Identiﬁcation of some oppor-
tunistic pathogens, such as pneumocystis and CMV, has led
to improved surveillance, prophylaxis, early treatment, and
improved outcomes. Newer methods allow characterization
of known and novel bacteria, viruses, and fungi in the
microbiome [114]. A shotgun metagenomic sequencing
approach, for example, resulted in the identiﬁcation of a new
colitis-associated pathogen [115].
Trial design
The committee proposed prospective collection of addi-
tional biospecimens (stool, sputum) from patients undergo-
ing allogeneic transplantation and enrolled on BMT CTN
1202. Collected specimens will undergo central shotgun
metagenomic sequencing. Shannon diversity index of mi-
crobial phyla will be calculated to quantify microbial di-
versity in each specimen. Spearman’s rank correlation
coefﬁcient will be calculated to determine the strength of the
correlation between Shannon diversity index and outcomes.
The genome sequences of novel organisms will be assembled
and deposited to the National Center for Biotechnology In-
formation. Unsupervised hierarchical clustering of cases/
controls will be performed to identify “microbiome” com-
positions or new organisms associated with RRT.
Feasibility and logistics
Feasibility of this trial is greatly enhanced by leveraging
the evaluations and data collection schedule and forms in
place for BMT CTN 1202. Specimens would be collected at the
same time points as the blood samples collected on BMT CTN
1202 (weekly from day 0 through day 28, and on days 42, 56,
and 91). A detailed kit and protocol for sample collection and
shipment would be provided; samples would be stored in a
central repository.
Summary of Discussion
Enthusiasmwas high for the development of a composite
health status risk score to improve the selection of older
patients for HCT. The additional collection of biospecimens
for future genetic and epigenetic analysis was recommended.
There was general agreement for the need for earlier detec-
tion of pulmonary toxicity and the development of an
observational trial of PFT and possibly novel imaging bio-
markers. Trials of novel early therapeutic intervention,
however, require further preliminary data before going for-
ward, Finally, the potential for an improved understanding of
microbiome alterations during HCT and the discovery of
new pathogenic microbes by metagenomic sequencing
techniques was acknowledged but felt not to be feasible as a
standalone trial at this time.
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RECONSTITUTION COMMITTEE
Current State of the Science
Despite the introduction of multiple effective antimicro-
bial agents, more accurate diagnostics, and advances in anti-
infective strategies, infection remains 1 of the most common
causes of serious morbidity and death after HCT. Suboptimal
or delayed immune reconstitution is the major risk factor
for this.Strategy 1: Randomized Phase II Trial of Adoptive
Immunotherapy Using Banked Third-Party CMV-speciﬁc
T Cells for Refractory CMV Infection [Developed Jointly
with the Gene and Cell Therapy Committee]
Hypothesis
Adoptive immunotherapy using CMV-speciﬁc T cells can
improve control of refractory CMV infection compared with
antiviral drug therapy.
Background and signiﬁcance
CMV mortality decreased with the introduction of effec-
tive antiviral drugs but substantial challenges remain [116].
CMV-speciﬁc T cell adoptive therapy has been shown in
small studies to be safe and effective for prevention and
treatment of CMV infection [86,117]. The utility of adoptive
immunotherapy in refractory CMV infection has not been
studied in a multicenter randomized trial.
Trial design
The committee proposed a randomized phase II study in
allogeneic HCT recipients with refractory CMV infection
(persistent DNAemia despite 2 weeks of anti-CMV drug
therapy, and not receiving prednisone >1 mg/kg/day). Sub-
jects would receive either banked CMV-speciﬁc T cells or
placebo, to be given on days 1, 8, and 15 after study entry.
Patients on both arms would continue to receive anti-CMV
drug therapy. Approaches to antiviral drugs and tapering of
immunosuppression would be standardized. The primary
endpoint would be the incidence of CMV disease [118] in a
time-to-event analysis. Secondary clinical, safety, clinical,
virologic, immune, and survival endpoints would be assessed
over 6 months. Block randomization and subset analysis will
be conducted in those receiving .5 and > .5 mg/kg/day of
prednisone.
Feasibility and logistics
We estimate DNAemia to occur in 55% of CMV-
seropositive patients. Twenty-nine percent of these
patients will develop persistent DNAemia, and 22% of
persistently DNAemic patients will develop disease [119]. We
expect the response rate to CMV-speciﬁc cells to be 74% [86],
thereby reducing CMV disease rates from 22% to 6%. We
anticipate approximately 90 patients per armwill be needed
to demonstrate this difference. Given that there about 4000
allotransplantations per year in the United States in CMV-
positive patients, there should be about 650 eligible pa-
tients a year, making accrual in 2 years feasible.Strategy 2: Randomized Phase II/III Trial of a Novel
Parainﬂuenza Virus (PIV) Entry Inhibitor in HCT
Recipients with PIV Upper Respiratory Tract Infection
Hypothesis
DAS181 (Ansun Biopharma, San Diego, CA) given for
treatment of PIV upper respiratory tract infection (URTI) inHCT recipients will reduce progression to lower respiratory
tract disease (LRTD).
Background and signiﬁcance
PIVs are major respiratory tract pathogens, which can
cause fatal viral LRTD and long-term airﬂowobstruction after
HCT [120e123] and for which there are no effective therapy
[124]. PIV URTI is a major risk factor for LRTD [120,121].
DAS181 is a novel sialidase viral receptor blocker on respi-
ratory tract epithelial cells [125]. DAS181 is active against
several respiratory viruses (including PIV and inﬂuenza)
[126,127] and is currently in a phase II trial in HCT recipients
with PIV LRTD.
Trial design
The committee proposed a phase III trial in which HCT
recipients presenting with documented PIV URTI would be
randomized 2:1 to either DAS181 or placebo for 7 days. The
primary endpoint would be time to progression to LRTD.
Secondary clinical and physiologic endpoints would also be
assessed.
Feasibility and logistics
The rates of symptomatic PIV infections are 7% to 8% [122]
in 2 core centers of the BMT CTN. If the rate is similar in all
HCT centers, there should be more than 1000 eligible pa-
tients in the United States annually. We estimate the pro-
gression rate in the placebo group to be w15%. With an
estimated w280 patients, the study would have 82% power
to detect a reduction from 15% to 5%. Recruitment should be
feasible in 2 to 3 years.
Strategy 3: Stepped Intervention Program to Reduce
Infections in Allogeneic HCT Recipients
Hypothesis
A multifaceted stepped intervention using an evidence-
based infection prevention guidelines checklist with feed-
back of post-HCT infection rates in allogeneic HCT recipients
will reduce rates of CMV disease and preventable bacteremic
and fungal infections.
Background and signiﬁcance
Prevention strategies shown to reduce serious infections
after HCT have been codiﬁed in guidelines [128]. Unfortu-
nately, adherence to guidelines is variable [129] due to dif-
ferences in systems and individuals [130]. Hospital safety
studies show that barriers to guideline implementation can
be overcome by a multifaceted approach [130e132], using an
unambiguous checklist with interventions linked in time and
space and reliance on systems, rather than on the actions of
individual clinicians. Outcomes can be improved with use of
technology to “ﬂag” data, follow and report outcomes, and
suggest actionable responses.
Trial design
The committee proposed a 3-year multicenter pro-
spective, interventional, nonrandomized, stepped, quality-
improvement cohort study designed to improve
implementation of strategies to prevent infections in allo-
geneic HCT recipients. The primary intervention will be the
use of pretransplantation and post-transplantation (weekly)
goals checklists up to day 100 to improve implementation of
evidence-based prevention strategies, tracking of severe
infection data, and continuous feedback of guidelines
adherence and infection rates.
Table 4
Deferred Late Effects/Quality of Life Trials
Domain Rationale for Deferral
Preventive care Smoking cessation e no preliminary data
Vaccinations e could only be in a limited
number of centers and may not need the
Network
Vitamin D supplementation e appropriate
endpoints unclear
Survivor support Survivorship care plan e ongoing funded
multicenter study
Internet-based survivorship support e ongoing
funded multicenter study (INSPIRE)
Survivorship support package e would require
extensive development
QOL, economics Usually appropriate as secondary endpoints
Late effects Cardiotoxicity e need very late follow-up,
expensive study, rare outcome
Sexual dysfunction e lack of preliminary data
Iron overload e unclear clinical implications,
premature for an intervention study
Infertility e lack of a feasible intervention
Avascular necrosis e lack of a feasible
intervention
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opment of BMT CTN infection deﬁnitions and prevention
guidelines for the trial, (2) pilot infection tracking system
(this will enable ﬁnalization of sample size estimates), and
(3) implementation of prevention checklist and continuous
feedback system. The primary endpoint will be the serious
composite infection (SCI) rate (severe Gram-negative bacte-
rial infections, CMV syndrome and/or disease, and invasive
fungal infections) at day 100. Poisson regression modeling
will be used to compare rates before, during, and up to
2 years after implementation of the primary intervention.
Secondary endpoints will be compliance with guidelines,
health care utilization measures, incidences of each serious
infection, and transplantation-related mortality.
Feasibility and logistics
Historically, the estimated 3-month SCI rate is 30%.
Through the application of a multifaceted stepped interven-
tion (single arm), with a sample size of 246, a SCI rate of 20%
(10% reduction from the historical rate) can be estimated to a
desired precision of 5%with 95% conﬁdence. The historical SCI
rate measured after pilot data collection will be used to
conﬁrm sample size estimates, as these estimates are depen-
dent on the actual baseline SCI rate measured after year 1.
Summary of Discussion
There was considerable enthusiasm for both Strategies 1
and 2, which were considered high priorities for the
network in the near future. It was felt that Strategy 1
addressed a novel approach to a signiﬁcant problem that
would require the Network to be successfully tested.
Concern was expressed about the estimate of the endpoints
in that they were derived some time ago and may not
reﬂect the event rates in a contemporaneous cohort of pa-
tients and in recipients of T cellereplete grafts. Moreover,
quantitative PCR detection assays have replaced older, less
sensitive antigen assays. The committee indicated that a
current prospective study in allogeneic T cellereplete HCT
recipients is underway and will be used to revise the esti-
mates of the event rate. If this study indicates the event rate
is too low, options include conﬁning the study population to
high-risk patients (patients receiving T celledepleted or
cord blood grafts and/or those receiving antithymocyte
globulin or alemtuzumab) or discussing with the Food and
Drug Administration an alternative or composite endpoint.
For the respiratory syncytial virus antiviral trial in Strategy
2, there also was considerable enthusiasm. No major con-
cerns were noted. Although there was enthusiasm for the
stepped-intervention program in Strategy 3, concerns were
raised regarding the current paucity of data to support key
endpoint estimates and the need for a method to select
centers with a heterogeneity of practices, as some centers
may already have in place approaches that standardize
adherence to guidelines practices. It was felt that there
should be a pilot study to provide good estimates of how
much of a reduction in SCI rates might be expected after
adoption of the intervention.
COMMITTEE 12: LATE EFFECTS/QOL/ECONOMICS
Current State of the Science
The BMT CTN has conducted 1 trial of training in exercise
and/or stress management to improve QOL. However, many
BMT CTN trials have QOL or economicmeasures as secondary
endpoints. After reviewing the pertinent literature, the
committee focused on a primary prevention trial for boneloss. The committee wrote 3 white papers to codify methods
to incorporate secondary endpoints of late effects, QOL, and
economic outcomes into other BMT CTN clinical trials
wishing to study these endpoints, available at https://
web.emmes.com/study/bmt2/SOSS.html.
The committee considered multiple other research
questions, but deferred them because of the reasons listed in
Table 4.
Strategy 1: Randomized, Placebo-controlled Study to
Evaluate the Efﬁcacy of Zolendronic Acid for Prevention
of Bone Loss after Allogeneic HCT
Hypothesis
Administration of zoledronic acid will prevent bone
mineral density (BMD) loss during the ﬁrst year after allo-
geneic HCT, as demonstrated in a single-center study [133].
Background and signiﬁcance
Osteopenia is found in 20% to 30% of patients before
transplantation, whereas 10% to 20% already have osteopo-
rosis [134]. Studies show that signiﬁcant bone loss occurs in
the ﬁrst 6 to 12months after HCT [135], and remineralization
can take years, if it occurs at all [136]. A single-center study
has shown an 8% cumulative incidence risk of fracture at
3 years after HCT as well as decline in BMD with continued
exposure to risk factors such as corticosteroids and CNIs
[137]. Low BMD is a risk factor for fractures.
Trial design
The committee proposed a phase III randomized, placebo-
controlled trial comparing a single 5 mg i.v. infusion of
zoledronic acid to placebo. The randomization would be
stratiﬁed to balance factors that may correlate with bone loss
or response assessment (baseline BMD, steroid exposure,
center). The primary endpoint is the change in BMD (g/cm2)
as measured by DEXA scan. A sample size of 130 patients per
group will give 90% power to detect a .5 standard deviation
difference in the femoral BMD between enrollment and
1 year after transplantation, assuming we are unable to
evaluate 30% at 1 year because of death or missing DEXA
data. Both arms will receive calcium and vitamin D. Patients
with baseline osteoporosis or prior bisphosphonate use will
be excluded from the trial.
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Zoledronic acid is approved for the prevention and
treatment of bone loss at the proposed dose. There are an
estimated 5000 potentially eligible patients in the United
States annually, so recruitment should be brisk.
Strategy 2: Standardize Collection of Patient-Reported
Outcomes, Late Effects and Economic Data in BMT CTN
Therapeutic Trials
Background and recommendation
There is a growing interest in comparing the outcomes of
different therapies beyond traditional endpoints of survival,
NRM, and disease control. Many protocol teamswould like to
collect data on QOL, symptoms, late effects, or economic
endpoints. They may be motivated by anticipated differences
between treatment approaches, or because the design of
their trial will support many secondary studies in the future.
The clinical data and specimens collected for most BMT CTN
clinical trials represent a robust resource upon which
collection of QOL, late effects, and cost data for selected
studies is likely to deliver high value. The BMT CTN should
promote a core set of measurement tools for these endpoints
and standardize approaches to collection of these data types
to ensure useful and interpretable data. Not all trials will
include these endpoints, but those that do should have a
standardized approach.
Feasibility and logistics
The committee drafted 3 white papers to outline best
practices regarding collection of these data types. These pa-
pers provide detailed recommendations for study design,
implementation, and conduct, and suggested wording for
protocols and consent forms. Members of the committee are
available to help protocol teams integrate these secondary
endpoints into their trials and to help teams monitor data
collection while the trial is ongoing.
Summary of Discussion
There was high enthusiasm for Strategy 1. The primary
issues raised concerned the most appropriate time for
enrollment (before HCT versus day þ100 versus when ste-
roids are started), identifying appropriate high-risk patients
for enrollment, the wisdom of including patients with
normal BMD, the duration of follow-up, how the DEXA scans
and zoledronic acid would be ﬁnanced, andwhethermarkers
of bone turnover should be incorporated into the trial.
Although these issues require resolution, there was high
enthusiasm for this trial. Concerning Strategy 2, the primary
suggestion was to coordinate with the European Society for
Blood and Marrow Transplantation and other interested
groups to make sure that international standardization is
incorporated whenever possible.
COMMITTEE 13: CLINICAL TRIAL DESIGN
The SOSS clinical trial design committee identiﬁed several
important issues to be considered when developing clinical
trials in HCT.
Incorporation of Controls in the Design of Phase II Trials
A phase II study using a historical control rate makes
interpretation of results difﬁcult because unrecognized
changes in patient characteristics over time can increase the
probability of a false positive or false negative result
[138,139]. Including a concurrent control group improves the
design but requires substantially more patients for sufﬁcientstatistical power. Ideally, the control arm is randomized,
although a nonrandomized convenience sample of contem-
poraneous patients could be used instead. A compromise
involves using CIBMTR registry data with regression
methods to partially adjust for differences between trial
and registry patients. This approach is most appropriate
when eligibility criteria can be easily reproduced and
when outcomes and well-established risk factors are
routinely collected by the registry. Differential patterns of
assessment can be addressed by including additional
prospectively enrolled CIBMTR patients, subject to
additional participant consent. BMT CTN 1203 (Amulticenter
phase II trial randomizing novel approaches for GVHD pre-
vention compared to contemporary controls) uses prospec-
tive enrollment of a registry control group receiving
tacrolimus þ methotrexate as GVHD prophylaxis. Another
valuable source of control patients is BMT CTN 1202, where
protocol-speciﬁed GVHD and toxicity assessments and bio-
specimens augment registry data. The Graft Sources SOSS
committee proposed a haplo-identical HCT trial that could
possibly use a registry control. Enrollment occurs just before
HCT, facilitating identiﬁcation of registry control patients,
and the primary endpoint is a standard PFS outcome.Patient Enrichment for Studying Infrequent Outcomes
A trial studying a new treatment for an infrequent but
serious outcome risks exposing many patients to a treatment
that may beneﬁt few patients, because a large sample size is
needed to identify a small treatment effect. Although eligi-
bility could be restricted to patients with a higher likelihood
of the outcome, drawbacks of such an “enrichment” strategy
include slower accrual, less generalizability of the results,
and the need for a randomized control group when it is
difﬁcult to identify higher-risk registry patients. The Pedi-
atric Indications and Approaches SOSS committee proposed
a relapse prevention trial in ALL that identiﬁes patients at
high risk of relapse based on pre-HCT MRD and absence of
acute GVHD by day 55 after HCT, making detection of a risk
reduction more feasible. However, the day 55 eligibility cri-
terion makes it difﬁcult to identify appropriate control pa-
tients from a registry, leading to the need for a randomized
control arm.Biomarkers in Eligibility Criteria as an Enrichment
Strategy
Biomarkers may be used to identify high-risk patients for
study inclusion, but the need for a pre-enrollment laboratory
measurement adds logistical complexity. The biomarker’s
predictive value can be established using standard metrics,
such as Akaike Information Criterion, area under the receiver
operating characteristics curve, and Brier score, or more
controversial metrics, such as standardized-net beneﬁt or
net-reclassiﬁcation index [140]. Interlaboratory measure-
ment variability of the assay should be assessed as well as
consistency of the biomarker’s ability to predict outcomes
across subgroups of patients. The GVHD SOSS committee is
proposing the use of a 3-biomarker panel to identify patients
with high-risk acute GVHD and poor prognosis for survival.
The beneﬁt of this grading will be gauged by its ability to (1)
identify a large enough group of high-risk patients to sufﬁ-
ciently power clinical studies, and (2) stratify GVHD severity
among patients better than standard clinical assessment,
such as the Consensus criteria.
Table 5
2014 SOSS High Priority Trials
Committee Priority
Leukemia Phase III study of postallogeneic transplantation maintenance using FLT3 inhibition versus placebo in
patients with FLT3þ AML and azacytidine versus placebo in those with FLT3-AML
Lymphoma Phase III study of postautologous transplantation maintenance using ibrutinib versus placebo in patients
with relapsed or refractory DLBCL
Nonmalignant disease Phase III study of autologous transplantation versus standard therapy for MS
Pediatric indications Phase III study of post-transplantation maintenance using moxetumomab or inotuzumab versus placebo in
pediatric and adult patients with B cell ALL
Pediatric outcomes Phase II study of daily versus alternate day dosing of steroids for chronic GVHD
Optimal donor and graft source Phase II study of haploidentical peripheral blood stem cells and PTCY after myeloablative conditioning
GVHD In low-risk patients, randomized phase II studies of novel agents versus steroids, and in high-risk patients,
randomized phase II studies of novel agents plus steroids versus steroids alone
Gene and cell therapy Phase III study of haploidentical donor NK cells for AML
Comorbidity/RRT Development of a more robust risk assessment method incorporating biomarkers and geriatric assessment tools
Infection/immune reconstitution Phase III study of CMV-speciﬁc T cell adoptive therapy.
Infection/immune reconstitution Phase II study of a novel PIV entry inhibitor in HCT recipients with upper respiratory tract infection
Late effects Phase III randomized trial of zoledronic acid versus placebo for prevention of bone loss after allogeneic HCT
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Assessment of multiple promising new agents is often
slowed by administrative hurdles in multicenter trials
including protocol development and approval. A “plug-in”
protocol could be written with a primary and backup agent
so that completion of accrual to the primary agent (either
through study completion or early stopping) triggers a
switch to the backup agent without delay in implementation.
Then a protocol amendment could add another backup
agent, leaving a primary and secondary treatment to still be
studied. Short-term endpoints, if reasonably likely to predict
clinical beneﬁt, can facilitate quick decisions of whether to
switch to a phase III trial with that treatment or to switch to
the next agent.
Novel Endpoints in HCT
Quantitative or ordinal endpoints typically require
smaller sample sizes than PFS or time-to-event data, but
analysis must appropriately handle patients who die or are
otherwise not evaluable. Possible strategies include impu-
tation (a procedure for inserting a value to stand in for
missing data) and use of rank statistics for hypothesis testing,
or an analysis conditional on survival. Imputation helps to
preserve the intention-to-treat principle and may be less
sensitive to bias due to differences in survival. However, it
typically requires more patients than a conditional analysis
because this approach shrinks the measurement distribu-
tions closer together because of the inclusion of patients who
die. Careful consideration of study eligibility and timing of
the intervention can reduce the impact of mortality on the
outcome. The Late Effects SOSS committee proposed a study
of zoledronic acid for prevention of bone loss, where the
outcome is change in femoral neck BMD from 100 days to
1 year after transplantation. Restricting eligibility to early/
intermediate disease with good performance score can help
minimize the impact of the competing risk of death.
Summary
Clinical trials in HCT are difﬁcult because of the rarity of
the diseases being studied and multiple competing risks in
the post-transplantation setting. Strategies discussed above
including comparisons to a registry control, patient enrich-
ment and use of biomarkers, rapid assessment of new agents,
and use of novel endpoints in HCT all have the potential to
improve feasibility of HCT trials, although the advantages
and disadvantages of each strategy must be carefullyconsidered. Although the committee’s preference is for ran-
domized controls, it recognizes that alternative designs must
also be considered.
Prioritization
As noted earlier, after the committee presentations and
open discussion, the SOSS Planning Group, committee chairs,
and outside reviewers met, discussed the individual pro-
posals, and formed a prioritization list. The 12 concepts listed
in Table 5 received a high level of enthusiasm from the re-
view group. They are listed in the order of presentation at the
meeting. The highest priorities were reserved for those
studies addressing impactful questions, with adequate pre-
liminary data and no obvious impediments to their conduct.
Many of the concepts not given high priority asked impor-
tant questions and, if preliminary data are generated or
certain barriers can be circumvented, might become equally
compelling in the future.
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